GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Duality Biotherapeutics 9606.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

104.20

-0.67%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.10bn

FY2022FY2025

Net income

−CN¥2.94bn

FY2022FY2025

Free cash flow

CN¥210.7m

FY2022FY2025

Shareholders' equity

CN¥2.83bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
RevenueCN¥2.10bnCN¥2.26bnCN¥2.08bnCN¥1.9m
Research and developmentCN¥943.0mCN¥974.6mCN¥651.1mCN¥395.9m
Operating income−CN¥484.9m−CN¥220.1mCN¥910.1m−CN¥429.3m
Net income−CN¥2.94bn−CN¥1.22bn−CN¥416.4m−CN¥450.9m
Diluted earnings per share-33.23-14.71-5.01-5.42

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assetsCN¥4.54bnCN¥2.43bnCN¥1.75bnCN¥540.2m
Cash and short-term investmentsCN¥3.99bnCN¥1.62bnCN¥1.32bnCN¥437.9m
Total liabilitiesCN¥1.71bnCN¥4.79bnCN¥3.06bnCN¥1.44bn
DebtCN¥174.5mCN¥3.05bnCN¥2.14bnCN¥3.0m
Shareholders' equityCN¥2.83bn−CN¥2.36bn−CN¥1.31bn−CN¥895.9m
Shares outstanding89m83m83m83m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operationsCN¥226.7mCN¥332.9mCN¥950.9m−CN¥348.8m
Capital spending−CN¥16.0m−CN¥36.3m−CN¥41.8m−CN¥25.9m
Free cash flowCN¥210.7mCN¥296.6mCN¥909.1m−CN¥374.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥127.7mCN¥127.7mCN¥362.7mCN¥362.7mCN¥715.7mCN¥715.7mCN¥558.2mCN¥538.4m
Operating income−CN¥563.1m−CN¥563.1m−CN¥345.9m−CN¥345.9mCN¥62.3mCN¥62.3m−CN¥134.9m−CN¥192.3m
Net income−CN¥534.4m−CN¥534.4m−CN¥303.4m−CN¥303.4m−CN¥1.21bn−CN¥1.21bn−CN¥563.7m−CN¥318.0m
Diluted earnings per share-5.94-5.94-3.42-3.42-13.63-13.63-6.78-3.82
Cash from operations——−CN¥230.0m−CN¥230.0mCN¥343.0mCN¥343.0mCN¥309.0m−CN¥184.0m
Capital spending——−CN¥5.0m−CN¥5.0m−CN¥3.0m—−CN¥11.0m−CN¥8.0m
Free cash flow——−CN¥235.0m−CN¥235.0mCN¥340.0m—CN¥298.0m−CN¥192.0m
Total assetsCN¥4.08bnCN¥4.08bnCN¥4.53bnCN¥4.53bnCN¥4.87bnCN¥4.87bnCN¥2.43bnCN¥2.10bn
Cash and short-term investmentsCN¥3.54bnCN¥3.54bnCN¥3.93bnCN¥3.94bnCN¥4.31bnCN¥4.31bnCN¥1.62bnCN¥1.30bn
DebtCN¥283.1mCN¥283.1mCN¥174.5mCN¥169.9mCN¥79.1mCN¥75.6mCN¥3.5mCN¥3.7m
Shareholders' equityCN¥1.69bnCN¥1.69bnCN¥2.83bnCN¥2.83bnCN¥3.39bnCN¥3.39bn−CN¥2.36bn−CN¥1.74bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022
Operating margin-23.1%-9.7%43.7%-23036.4%
Net margin-140.1%-54.1%-20.0%-24193.1%
Return on equity-104.1%52.0%31.8%50.3%
Return on assets-64.9%-50.3%-23.8%-83.5%
Free cash flow yield1.1%1.8%4.8%—
Revenue growth-7.1%8.7%111558.8%—
Earnings growth140.6%193.8%-7.6%—
Current ratio3.61x0.49x0.52x0.33x
Debt to equity0.06x-0.00x-0.00x-0.00x
Equity ratio62.3%-96.7%-74.9%-165.9%
Interest coverage-353.16x-755.97x4156.14x-4914.44x
R&D as a share of sales44.9%43.1%31.3%21243.1%
Buybacks as a share of market value-6.5%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue940.8%——
Operating income4.1%——
Net income86.9%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-8.1
Price to sales11.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.